Non-Small Cell Lung Cancer

May 8th 2024

Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.

May 3rd 2024

Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point.

April 27th 2024

This analysis evaluated patient-related outcomes between those who did and did not receive consolidation durvalumab after chemoradiotherapy for unresectable stage III non–small cell lung cancer.

April 24th 2024

For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.